Chemocentryx, Inc.

Millennium Pharmaceuticals Limited

Amgen Inc.

Other

Cor Therapeutics, Inc.

Penglie Zhang

Sreenivas Punna

Yibin Zeng

Pingchen Fan

Viengkham Malathong

Rebecca M Lui

Venkat Reddy Mali

Rajinder Paul Singh

Jay Patrick Powers

Hiroko Tanaka

Ju Yang

Christopher W Lange

Jeffrey P McMahon

Dean R Dragoli

Xi Chen

Manmohan Reddy Leleti

Antoni Krasinski

Junfa Fan

Andrew M K Pennell

Jaroslaw Kalisiak

Lianfa Li

Bing-Yan Zhu

Yandong Li

Robert M Scarborough

Darren J McMurtrie

Wenrong Huang

Chao Yu

Erick A Goldman

Wei Yu Chen

Yonghong Song

Lingyan Wang

Wenhao Li

Howard S Roth

Jingmei Zuckett

Daniel J Dairaghi

Edward J Sullivan

William L Thomas

Juan Carlos Jaen

Kevin Lloyd Greenman

John J Kim Wright

Joanne Tan

Subhabrata Bapi Sen

James Bradley Aggen

Thomas J Schall

Solomon Ungashe

Trevor T Charvat

Yuan Xu

Cheng Hu

Aaron Robert Novack

Anita Melikian

Israel Charo

J J Kim Wright

Matthew J Walters

Mark M Gleason

Jeffrey P Mcmahon

Yu Wang

Valentino J Stella

James J Campbell

Shichang Miao

Kwok Yau

Ryan J Scamp

Yang Song

Wei Chen

Andrew M Pennell

Zhaozhong Jon Jia

Brian E McMaster

Ting Su

Kim A Kane-Maguire

Shijie Li

Karen Ebsworth

Jeffrey P McMAHON

Heiyoun Jung

Daniel R Marshall

Aubrie Harland

Shawn M Bauer

Charles K Marlowe

Valeri Martichonok

J J Wright

Andrew Mk Pennell

Lane Clizbe

Willy Teng

Robert M Scarborough, Deceased

John Woolfrey

Brandon Doughan

Kenken Luong

Darren J McMURTRIE

Jarek Kalisiak

William D Thomas

Aaron Novack

Jeffrey Mcmahon

Hiroko Tankaka

John J Wright

Daniel Joseph Dairaghi

Subhabrata Sen

Daniel Dairaghi

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, A, Z, Xand n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

2-oxindole compounds

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1′): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

Substituted tetrahydropyrans as CCR2 modulators

Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Aryl sulfonyl compounds as CCR6 inhibitors

The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

Compounds are provided as inhibitors of CXCR2, having the structure:

Inhibitors of CXCR2

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies

Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Y, Y′, and the subscripts m and n are as defined herein.

Indanes as PD-L1 inhibitors

Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.

Processes and intermediates in the preparation of C5aR antagonists

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

CXCR7 antagonists

Compounds are provided as chemokine inhibitors having the structure:

Modulators of chemokine receptors

Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Deuterated compounds as immunomodulators

Growing community of inventors

Foster City, CA, United States of America

Penglie Zhang